Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

For years, employers have sought to streamline their relationships with drugmakers to lower costs. But until recently, there ...

CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Eli Lilly chairman and CEO David Ricks joins 'Squawk on the Street' to discuss the path to becoming a trillion dollar company ...

Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area ...

Humana’s CenterWell pharmacy will dispense GLP-1 weight loss drugs made by Eli Lilly as part of a new program for employers ...

Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.

Shares of the biotech company surged 1,681% in 2025, making it the best performer in the Stoxx Europe 600 by a wide margin.

Schrödinger (SDGR) stock and Revvity (RVTY stock are in focus as firms join Eli Lilly (LLY) to integrate their software with ...

Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...